VPHM was upgraded by a couple of brokers, and OPTR was also upgraded related to C. Difficule treatments.
{[No, I'm not playing VPHM this time]}
15-Dec-11 07:50 ET VPHM
ViroPharma upgraded to Strong Buy at WBB Securities; tgt raised to $31.25 (27.80 )
WBB Securities upgrades VPHM to Strong Buy from Buy and raises their tgt to $31.25 from $24.50 following the announcement that the FDA approved its supplemental New Drug Application for labeling modernization of Vancocin (vancomycin hydrochloride capsules, USP). Firm notes VPHM believes this sNDA qualifies Vancocin for three years of exclusivity, during which generic vancomycin capsules will not be approvable. The firm believes this is a stunning development, which is likely to provide Vancocin with three more years of exclusivity, which will translate into continuing revenue and positive net income for VPHM.
15-Dec-11 06:54 ET VPHM
ViroPharma target raised to $32 at Oppenheimer (27.77 )
Oppenheimer raises their VPHM tgt to $32 from $23 after VPHM announced the modernization of labeling for Vancocin which became effective upon the FDA's approval of the sNDA. The firm believes Vancocin will have exclusivity for the next three years, effectively removing the overhang associated with a near-term generic threat. They believe VPHM's pending Citizens Petition has been positively impacted by suggestions to require generic Vancocin prove in vitro bioequivalence in addition to utilizing a modern assay to measure dissolution of the drug.
15-Dec-11 08:43 ET OPTR
Optimer Pharma: Extension of Vancocin brand should sustain marketing leverage for Optimer - Brean Murray (11.96 )
Brean Murray believes the news that Viropharma (VPHM) has received a sNDA approval for Vancocin, providing for 3 years of exclusivity, is a material positive for Optimer. It believes that concerns over a near-term generic vanc has limited upside to the stock given that Optimer is selling Dificid into a market where Vancocin has been used as the standard of care for more severe and relapsed cases of CDI. Firm believes it is a much easier argument to convince doctors to use Dificid when the alternative is another expensive drug with an inferior profile than a cheap generic drug with an inferior profile.
Take time to look around, even on a down day!
